HEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Stage IV Adrenocortical Carcinoma (ACC)
Source: Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 13, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage IV Adrenocortical Carcinoma
Treatment options for stage IV ACC include:
Source links and citations
Chemotherapy with mitotane.
Chemotherapy with mitotane plus streptozotocin or mitotane plus etoposide, doxorubicin, and cisplatin, as evidenced by the NCT00924144 phase III clinical trial.[1]
Source links and citations
Radiation therapy to bone metastases.
Surgical removal of localized metastases, particularly for tumors that are functioning.
Insulin-like growth factor 1 receptor–inhibitors (under clinical evaluation).
Gossypol (under clinical evaluation).
Temporary palliation of disseminated ACC can sometimes be achieved with the chemotherapeutic agent mitotane. Although measurable partial remissions are unusual and are reported in only 20% to 30% of patients, palliation of hormone symptoms is commonly observed. Prolonged treatment with mitotane, however, is often limited by gastrointestinal and neurological toxicity. Local recurrences and selected sites of metastatic disease can sometimes be palliated surgically or with radiation therapy.[1,2]
Two other cytotoxic chemotherapy regimens may be effective and have been compared in a phase III clinical trial:[1]
Source links and citations
Streptozotocin plus mitotane.
Etoposide, doxorubicin, and cisplatin plus mitotane.
Clinical trials of other chemotherapy regimens are ongoing.
Many patients with functioning tumors who receive treatment experience reduced hormone production. In patients with increased hormone production, antisteroidogenic drugs, such as ketoconazole and metyrapone, and steroid receptor antagonists, such as spironolactone and mifepristone, should be considered.
Clinical trials, including phase I and II trials of newer chemotherapeutic and biological agents, are appropriate and should be considered.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice
Triangle